Shares of Bio-Techne Corp. TECH rose 3.72% to $75.25 Wednesday, on what proved to be an all-around favorable trading session ...

Bio-Techne TECH reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of 42 cents, which exceeded the Zacks ...

CEO Kim Kelderman highlighted 9% organic revenue growth for the quarter, driven by strong performance in biopharma end markets, particularly large pharma, which benefited GMP reagents and protein ...

Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode and the call will ...

Bio-Techne Corp (NASDAQ:TECH) reported stronger-than-expected earnings for the second quarter of fiscal year 2024, with adjusted earnings per share (EPS) of $0.42, surpassing the forecasted $0.39.

The firm's Protein Sciences segment saw revenues increase 7 percent, while the Diagnostics and Spatial Biology segment's revenues rose 12 percent.

Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, ...

Boston Scientific Corporation generated net sales of $4.561 billion during the fourth quarter of 2024, growing 22.4 percent on a reported basis, 23.1 percent on an operational1 basis and 19.5 percent ...

Bio-Techne Corp. (TECH) announced earnings for its second quarter that increased from last year and beat the Street estimates. The ...

OPEC oil output fell in January for a second month, a Reuters survey found, as a drop in exports from Nigeria and Iran offset ...

Bio-Techne beat second-quarter profit and revenue estimates on Wednesday, helped by growth in its protein sciences unit that makes products to develop therapies ...

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q4 CY2024 results topping the market’s revenue expectations, with ...